Investor Relations

01 June, 2023 in Investor Relations

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region

27 March, 2023 in Investor Relations

Nexalin Technology Provides 2022 Year-End Business Update

24 January, 2023 in Investor Relations

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

05 January, 2023 in Investor Relations

Nexalin Technology CEO Provides Letter to Shareholders

14 November, 2022 in Investor Relations

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder

20 September, 2022 in Investor Relations

Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering

15 September, 2022 in Investor Relations

Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering

17 May, 2021 in Investor Relations

9 SURPRISING FACTS ABOUT ANXIETY